Article snippet: WASHINGTON — The Senate on Thursday gave final approval to legislation to finance the Food and Drug Administration, clearing the measure for President Trump and tapping drug manufacturers once again to help pay for the federal review of prescription drugs and medical devices. The 94-to-1 vote came just hours after the Senate passed a separate bill expanding access to experimental treatments for people with terminal illnesses. This bill, the Right to Try Act, will now go to the House, where more than three dozen lawmakers have endorsed similar legislation. Mr. Trump is expected to sign the bill reauthorizing user fees to pay for the review of medical devices, brand-name drugs, generic drugs and biosimilars, which are copycat versions of costly biologic drugs made from living organisms. The House approved the user fee bill by voice vote on July 12. The vote on Thursday capped an often frustrating seven months for Republicans, who had hoped to churn out reams of conservative legislation with their control of both chambers and the White House. Since the failure of the Senate’s health care repeal bill last week, lawmakers have seemed resigned to more incremental successes. “We’re passing critical legislation, we’re confirming nominees to important positions,” Senator Mitch McConnell of Kentucky, the majority leader, said from the Senate floor on Thursday, citing a series of veterans bills and the confirmation this week of a new F.B.I. director, Christopher A. Wray. In... Link to the full article to read more
Senate Passes F.D.A. Funding and ‘Right to Try’ Drug Bills - The New York Times
>